ycopene and Vitamin E in men with minimal prostate cancer and rising PSA after radical prostatectomy. A double blind randomised placebo controlled cross-over study.
Completed
- Conditions
- Minimal prostate cancer and rising PSA after radical prostatectomy.
- Registration Number
- NL-OMON25453
- Lead Sponsor
- BASF Aktiengesellschaft.
- Brief Summary
Schroder FH, Roobol MJ, Boeve ER, de Mutsert R, Zuijdgeest-van Leeuwen SD, Kersten I, Wildhagen MF, van Helvoort A.<br> Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement. Eur Urol. 2005 Dec;48(6):922-30; discussion 930-1. Epub 2005 Oct 17.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 80
Inclusion Criteria
1. Status after radical prostatectomy with potential curative intent;
2. Rising PSA;
Exclusion Criteria
1. Current hormone therapy or hormone therapy during previous 12 months;
2. Orchidectomy;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Slope of the regression line through all two-weekly PSA measurements.
- Secondary Outcome Measures
Name Time Method Plasma levels of testosterone, estradiol, DHEA, DHT, and SHBG, and IGF-1 during the intervention as compared to placebo.